STOCK TITAN

Hyperfine (HYPR) Stock News, Jan-May 2026

HYPR NASDAQ

Hyperfine, Inc. develops and commercializes the Swoop® system, an FDA-cleared, AI-powered portable ultra-low-field magnetic resonance brain imaging system. News about HYPR centers on Swoop deployments across hospitals, emergency departments, ICUs, neurology offices, and international markets; regulatory clearances such as CE and UKCA marks; and Optive AI™ software updates tied to brain imaging workflows.

Company updates also cover quarterly results, clinical data and publications in stroke and neuroimaging, distributor and customer activity, financing arrangements, and healthcare-conference participation.

Rhea-AI Summary

Hyperfine (Nasdaq: HYPR) will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026 at 8:45 AM ET. A live audio webcast and archived recording will be available on the company’s Investors page. Management will also hold in-person meetings; scheduling is via Jefferies or the investor contact.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.89%
Tags
none
-
Rhea-AI Summary

Hyperfine (NASDAQ: HYPR) announced clinical use of the Swoop® portable MRI at All India Institute of Medical Sciences, New Delhi—the first bedside MRI deployed for routine clinical brain imaging in India. Radiosurgery Global is the exclusive distributor; AIIMS will use the system for stroke, ICU, trauma, neonatal, pediatric and neurosurgical care and clinical research.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.77%
Tags
none
-
Rhea-AI Summary

Hyperfine (Nasdaq: HYPR) will report first-quarter 2026 financial results on Tuesday, May 12, 2026. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET with a live audio webcast and archived recording available on the company’s Investors page. Participants should register at least 15 minutes early.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.77%
Tags
earnings date
Rhea-AI Summary

Hyperfine (Nasdaq: HYPR) received CE Marking and UKCA approval for its next-generation Swoop® system and the latest Optive AI™ software, enabling commercialization across the European Economic Area and the United Kingdom.

The next-generation Swoop, FDA-cleared in Q2 2025, delivers improved image quality and workflow; Optive AI adds multi-direction DWI for better small-stroke detection. Commercial launch in Europe and the UK is planned early Q3 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.04%
Tags
AI
-
Rhea-AI Summary

Horizon Technology Finance (NASDAQ: HRZN) provided a $40 million loan facility to Hyperfine (NASDAQ: HYPR), with $15 million funded at closing and up to $25 million available to support future commercial growth. The financing targets expansion of Hyperfine's FDA-cleared Swoop® point-of-care MR brain imaging system across hospitals and offices.

The facility is presented as supporting Hyperfine's commercial scale-up, a second-generation device rollout, and broader adoption of portable neuroimaging in acute and chronic care settings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.42%
Tags
none
-
Rhea-AI Summary

Hyperfine (Nasdaq: HYPR) reported Q4 and full-year 2025 results and a business update on March 18, 2026. Q4 revenue was $5.29M (+128% YoY) and full-year revenue was $13.56M. Q4 gross margin improved to 51%. Cash was $35.09M as of Dec 31, 2025.

Company secured equity and debt financing, obtained regulatory clearance in India, received a $3.7M Gates Foundation grant, and provided 2026 guidance of $20–22M revenue with reduced cash burn.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.72%
Tags
Rhea-AI Summary

Hyperfine (Nasdaq: HYPR) will report fourth quarter and full year 2025 financial results on Wednesday, March 18, 2026.

Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET; a live audio webcast and archived recording will be available on the company investor website. Participants are encouraged to register at least 15 minutes early.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.83%
Tags
earnings date
-
Rhea-AI Summary

Hyperfine (Nasdaq: HYPR) published the largest dataset to date on stroke detection with the Swoop® portable MRI, a prospective multi-center observational study of 95 patients published in Stroke: Vascular and Interventional Neurology. The next-generation Swoop with an advanced multi-directional DWI sequence detected lesions as small as 2.8 mm (0.15 mL), achieved 100% sensitivity and 100% specificity for lesions >1.0 mL, and reduced scan time by approximately 30%. The advanced DWI sequence was recently cleared by the FDA. Systems were provided under sponsored research agreements; the company was not involved in study design, analysis, or publication decisions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.08%
Tags
-
Rhea-AI Summary

Hyperfine (Nasdaq: HYPR) announced NEURO PMR study results presented January 16, 2026 showing the portable Swoop® MRI (0.064T) has high diagnostic concordance and superior patient experience in outpatient neurology clinics.

In a prospective, multi-center real-world study of 125 patients at two sites, portable MRI showed 92% blinded concordance with standard MRI for detecting intracranial pathology and 98% concordance in unblinded reviews with clinical history. Patients were 4× more likely to choose portable MRI and rated it superior across comfort, anxiety, claustrophobia, noise, and overall satisfaction (p<0.0001). Trained clinic staff operated Swoop without MR technologists, and scans are eligible for reimbursement under existing brain MRI CPT codes after site accreditation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
none
Rhea-AI Summary

Hyperfine (Nasdaq: HYPR) announced enrollment of the first patient in the Contrast PMR study, a prospective, multi-center trial to test contrast-enhanced ultra-low-field portable MRI using the Swoop system. The study will enroll approximately 70 patients across U.S. sites and will evaluate three endpoints related to visualization of brain lesions, including those tied to blood-brain barrier disruption. The trial is intended to support a future FDA 510(k) submission to expand the Swoop system's intended use to include gadolinium-based contrast agents, with a potential submission anticipated toward the end of 2026.

ClinicalTrials.gov identifier: NCT07296263. More information at HyperfineMRI.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.61%
Tags
none

FAQ

What is the current stock price of Hyperfine (HYPR)?

Hyperfine (HYPR) last closed at $0.5465.

What is the market cap of Hyperfine (HYPR)?

The market cap of Hyperfine (HYPR) is approximately $58.0M.